$5.3 M

ABIO Mkt cap, 12-Feb-2019
ARCA biopharma Net income (Q3, 2018)-1.6 M
ARCA biopharma EBIT (Q3, 2018)-1.7 M
ARCA biopharma Cash, 30-Sep-20188.1 M

ARCA biopharma Income Statement

Annual

USDFY, 2016FY, 2017

R&D expense

12.3m14.1m

General and administrative expense

4.3m4.6m

Operating expense total

16.6m18.7m

EBIT

(16.6m)(18.7m)

Interest expense

6.0k

Interest income

169.0k167.0k

Pre tax profit

(18.6m)

Income tax expense

61.0k

Net Income

(16.4m)(18.5m)

ARCA biopharma Balance Sheet

Annual

USDFY, 2013FY, 2015FY, 2016FY, 2017

Cash

16.8m38.8m7.4m8.7m

Current Assets

16.9m38.9m21.4m12.3m

PP&E

29.0k28.0k66.0k42.0k

Total Assets

17.1m39.6m24.6m12.4m

Accounts Payable

597.0k364.0k1.2m622.0k

Current Liabilities

1.5m1.5m2.4m2.1m

Total Liabilities

1.5m1.5m2.4m2.1m

Additional Paid-in Capital

90.5m134.1m134.7m141.3m

Retained Earnings

(96.1m)(112.5m)(131.0m)

Total Equity

38.1m22.2m10.3m

Financial Leverage

1 x1.1 x1.2 x

ARCA biopharma Cash Flow

Annual

USDFY, 2013FY, 2015FY, 2016FY, 2017

Net Income

(6.9m)(11.4m)(16.4m)(18.5m)

Depreciation and Amortization

26.0k19.0k24.0k27.0k

Accounts Payable

532.0k(431.0k)841.0k(583.0k)

Cash From Operating Activities

(5.3m)(10.5m)(15.0m)(17.5m)

Purchases of PP&E

(32.0k)(11.0k)(12.0k)(3.0k)

Cash From Investing Activities

(32.0k)(11.0k)(16.4m)12.9m

Cash From Financing Activities

19.2m34.0m34.0m5.8m

Interest Paid

3.0k4.0k4.0k6.0k

ARCA biopharma Ratios

USDY, 2018

Financial Leverage

1.1 x
Report incorrect company information